AVR Stock Overview
A structural heart company, engages in the designing, developing, and commercializing medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Anteris Technologies Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$9.68 |
| 52 Week High | AU$23.93 |
| 52 Week Low | AU$8.68 |
| Beta | 0.75 |
| 11 Month Change | -18.04% |
| 3 Month Change | -36.52% |
| 1 Year Change | -51.38% |
| 33 Year Change | -3.20% |
| 5 Year Change | 7.56% |
| Change since IPO | -87.26% |
Recent News & Updates
Recent updates
Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why
May 22
Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)
Jul 08Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now
May 07Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?
Feb 21
Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling
Dec 10Shareholder Returns
| AVR | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 10.0% | 0.5% | 1.5% |
| 1Y | -51.4% | 14.2% | 17.2% |
Return vs Industry: AVR underperformed the Australian Medical Equipment industry which returned 14.2% over the past year.
Return vs Market: AVR underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| AVR volatility | |
|---|---|
| AVR Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: AVR has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AVR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Wayne Paterson | anteristech.com |
Anteris Technologies Ltd, a structural heart company, engages in the designing, developing, and commercializing medical devices. The company’s lead product candidate is DurAVR, a transcatheter heart valve (THV) for the treatment of aortic stenosis. It also offers ComASUR, a delivery system that provides controlled deployment and placement of the DurAVR THV with balloon-expandable delivery, which allow precise alignment of the heart’s native commissures to achieve ideal valve positioning; and ADAPT, a patented anti-calcification tissue technology.
Anteris Technologies Ltd Fundamentals Summary
| AVR fundamental statistics | |
|---|---|
| Market cap | AU$194.91m |
| Earnings (TTM) | -AU$87.90m |
| Revenue (TTM) | AU$3.89m |
52.6x
P/S Ratio-2.3x
P/E RatioIs AVR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVR income statement (TTM) | |
|---|---|
| Revenue | AU$3.89m |
| Cost of Revenue | AU$2.25m |
| Gross Profit | AU$1.63m |
| Other Expenses | AU$89.53m |
| Earnings | -AU$87.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.16 |
| Gross Margin | 42.02% |
| Net Profit Margin | -2,260.86% |
| Debt/Equity Ratio | 5.3% |
How did AVR perform over the long term?
See historical performance and comparison